Beijing Dongfang Biotech Co., Ltd.
- Trials
- 0
- Subs
- 0
- People
- 0
- Links
- 0
Executive Summary
AI synthesisBeijing Dongfang Biotech Co., Ltd. is a Chinese biotech company with limited publicly available information, presenting significant due diligence challenges for US BD teams. The company appears to be clear of BIOSECURE Act designation currently, but the lack of transparency around corporate structure, pipeline, and leadership creates elevated risk for partnership evaluation. Without detailed pipeline or recent deal activity data, assessing strategic fit and commercial potential is difficult.
Structure: Corporate structure information is not publicly available, creating uncertainty around potential VIE arrangements or holding company layers typical of Chinese biotechs. The lack of subsidiary data and corporate governance transparency would require extensive due diligence to understand actual ownership and control structures.
BIOSECURE Risk
While currently clear of BIOSECURE designation, the limited transparency and lack of public information about government relationships or military connections creates uncertainty around future designation risk
Key Exposures:
- •Limited public disclosure of government relationships
- •Unclear corporate governance structure
- •Potential undisclosed subsidiary relationships
Mitigation: No publicly available information on BIOSECURE mitigation efforts or compliance programs
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity publicly reported
Approach: Exercise extreme caution - conduct extensive due diligence before any engagement given lack of transparency. Consider working through established intermediaries or consultants with local expertise.
Red Flags
- ⚠Complete lack of publicly available pipeline information
- ⚠No disclosed key management or scientific leadership
- ⚠Absence of recent corporate events or milestones
- ⚠Limited transparency around corporate structure and governance
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.